This study aimed at evaluation of relative survival rates of patients with stage IV liver cancers over the last decade in the United States: 2003-2012 using the Surveillance, Epidemiology, and End Results (SEER) Registry.
We used SEER*Stat Program to analyze 6-month and 12-month relative survival rates of 7252 American Joint Committee on Cancer (AJCC) Stage IV liver cancer cases by actuarial method. We compared relative survival rates among groups of patients categorized by sex, race, and age groups (≥60 and <60 years) using Z-test.
There was a statistically significant increase in both 6 and12-month relative survival rates for adenocarcinomas (26.6 Â± 0.6% and 13.5 Â± 0.4%) in comparison to other epithelial (10.5 Â± 1.9% and 5.9 Â± 1.5%) and unspecified (10.5 Â± 2.2% and 5.2 Â± 1.7%) neoplasms (P < 0.001). We also found a significant increase in both 6 and 12-month relative survival rates for age group <60 years (27.1 Â± 0.8% and 14 Â± 0.6%) in comparison to age group ≥60 years (24 Â± 0.7% and 12 Â± 0.6%, P < 0.001). Our study results didn't show a significant difference in survival when the cases were categorized according to sex or race.
Tumor's histology and patient's age can affect the relative survival rates in stage IV liver cancer cases while sex and race seem to have no effect on relative survival in such cases. These findings can help in designing better disease prognostic counselling and surveillance programs.
Clinical trial identification
All authors have declared no conflicts of interest.